BACKGROUND: The pathophysiological process of Alzheimer's disease (AD) begins many years before the emergence of clinical symptoms (preclinical AD). A hypothetical biomarker progression in the pathogenesis of AD has been suggested, beginning with the deposition of amyloid-β (Aβ) and followed by increases in neurofibrillary tangles, synaptic loss, hippocampal atrophy, and lastly, cognitive impairment. OBJECTIVE: We explored the effect of several risk factors for AD on the pattern of AD biomarker expression in normal subjects. METHODS: AD biomarker evidence was examined at baseline in 96 cognitively normal elderly subjects with none or at least one of the following: ApoE4+ allele, a maternal history of AD (mFHx), sleep-disordered breathing (SDB), and longitudinal evidence of decline to mild cognitive impairment or AD (decliners) at follow-up. RESULTS: Decliners and ApoE4+ subjects presented with expected reduced cerebrospinal fluid Aβ42, elevated P-tau and T-tau. In addition, decliners had fluorodeoxyglucose positron emission tomography hypometabolism in the medial temporal lobe. Individuals with mFHx demonstrated no Aβ42 effect, but had elevations in P-tau and T-tau. SDB was found to be associated with elevated Aβ42, P-tau and T-tau, as well as with reduced medial temporal lobe glucose metabolic rates. CONCLUSION: Our results indicate a heterogeneous biomarker expression, suggesting diversity of AD pathways in at-risk presymptomatic subjects.
BACKGROUND: The pathophysiological process of Alzheimer's disease (AD) begins many years before the emergence of clinical symptoms (preclinical AD). A hypothetical biomarker progression in the pathogenesis of AD has been suggested, beginning with the deposition of amyloid-β (Aβ) and followed by increases in neurofibrillary tangles, synaptic loss, hippocampal atrophy, and lastly, cognitive impairment. OBJECTIVE: We explored the effect of several risk factors for AD on the pattern of AD biomarker expression in normal subjects. METHODS:AD biomarker evidence was examined at baseline in 96 cognitively normal elderly subjects with none or at least one of the following: ApoE4+ allele, a maternal history of AD (mFHx), sleep-disordered breathing (SDB), and longitudinal evidence of decline to mild cognitive impairment or AD (decliners) at follow-up. RESULTS: Decliners and ApoE4+ subjects presented with expected reduced cerebrospinal fluid Aβ42, elevated P-tau and T-tau. In addition, decliners had fluorodeoxyglucose positron emission tomography hypometabolism in the medial temporal lobe. Individuals with mFHx demonstrated no Aβ42 effect, but had elevations in P-tau and T-tau. SDB was found to be associated with elevated Aβ42, P-tau and T-tau, as well as with reduced medial temporal lobe glucose metabolic rates. CONCLUSION: Our results indicate a heterogeneous biomarker expression, suggesting diversity of AD pathways in at-risk presymptomatic subjects.
Authors: M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler Journal: Proc Natl Acad Sci U S A Date: 2001-08-28 Impact factor: 11.205
Authors: Lidia Glodzik; Susan De Santi; Kenneth E Rich; Miroslaw Brys; Elizabeth Pirraglia; Rachel Mistur; Remigiusz Switalski; Lisa Mosconi; Martin Sadowski; Henrik Zetterberg; Kaj Blennow; Mony J de Leon Journal: J Alzheimers Dis Date: 2009 Impact factor: 4.472
Authors: Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Paul S Aisen; John Q Trojanowski; Leslie M Shaw; Matthew A Bernstein; Ronald C Petersen; Michael W Weiner; David S Knopman Journal: Arch Neurol Date: 2011-08-08
Authors: Madhav Thambisetty; Yang An; Michael Nalls; Jitka Sojkova; Shanker Swaminathan; Yun Zhou; Andrew B Singleton; Dean F Wong; Luigi Ferrucci; Andrew J Saykin; Susan M Resnick Journal: Biol Psychiatry Date: 2012-09-27 Impact factor: 13.382
Authors: Lidia Glodzik; Lisa Mosconi; Wai Tsui; Susan de Santi; Raymond Zinkowski; Elizabeth Pirraglia; Kenneth E Rich; Pauline McHugh; Yi Li; Schantel Williams; Fahad Ali; Henrik Zetterberg; Kaj Blennow; Pankaj Mehta; Mony J de Leon Journal: Neurobiol Aging Date: 2011-05-06 Impact factor: 4.673
Authors: Hélène Amieva; Mélanie Le Goff; Xavier Millet; Jean Marc Orgogozo; Karine Pérès; Pascale Barberger-Gateau; Hélène Jacqmin-Gadda; Jean François Dartigues Journal: Ann Neurol Date: 2008-11 Impact factor: 10.422
Authors: Lena L Law; Kate E Sprecher; Ryan J Dougherty; Dorothy F Edwards; Rebecca L Koscik; Catherine L Gallagher; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Sanjay Asthana; Mark A Sager; Bruce P Hermann; Sterling C Johnson; Dane B Cook; Barbara B Bendlin; Ozioma C Okonkwo Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Davide Bruno; Michel J Grothe; Jay Nierenberg; Henrik Zetterberg; Kaj Blennow; Stefan J Teipel; Nunzio Pomara Journal: Neuropsychologia Date: 2015-01-19 Impact factor: 3.139
Authors: Angela R Kamer; Elizabeth Pirraglia; Wai Tsui; Henry Rusinek; Shankar Vallabhajosula; Lisa Mosconi; Li Yi; Pauline McHugh; Ronald G Craig; Spencer Svetcov; Ross Linker; Chen Shi; Lidia Glodzik; Schantel Williams; Patricia Corby; Deepak Saxena; Mony J de Leon Journal: Neurobiol Aging Date: 2014-11-05 Impact factor: 4.673
Authors: Andrew W Varga; Margaret E Wohlleber; Sandra Giménez; Sergio Romero; Joan F Alonso; Emma L Ducca; Korey Kam; Clifton Lewis; Emily B Tanzi; Samuel Tweardy; Akifumi Kishi; Ankit Parekh; Esther Fischer; Tyler Gumb; Daniel Alcolea; Juan Fortea; Alberto Lleó; Kaj Blennow; Henrik Zetterberg; Lisa Mosconi; Lidia Glodzik; Elizabeth Pirraglia; Omar E Burschtin; Mony J de Leon; David M Rapoport; Shou-En Lu; Indu Ayappa; Ricardo S Osorio Journal: Sleep Date: 2016-11-01 Impact factor: 5.849
Authors: Kate E Sprecher; Barbara B Bendlin; Annie M Racine; Ozioma C Okonkwo; Bradley T Christian; Rebecca L Koscik; Mark A Sager; Sanjay Asthana; Sterling C Johnson; Ruth M Benca Journal: Neurobiol Aging Date: 2015-05-14 Impact factor: 4.673